Navigation Links
U.S. News & World Report Honors 7 SynCardia Certified Centers Among "Best Children's Hospitals" for Cardiology and Heart Surgery
Date:6/13/2013

TUCSON, Ariz., June 13, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that U.S. News & World Report has named seven SynCardia Certified Centers among the nation's "Best Children's Hospitals" for cardiology and heart surgery in its annual rankings for 2013-2014.

(Photo: http://photos.prnewswire.com/prnh/20130613/LA31329)

"The SynCardia temporary Total Artificial Heart has opened the flood gates in respect to the treatment possibilities for a quickly growing population of children in heart failure, including adolescents suffering from chronic rejection of their transplanted heart, end-stage heart failure accompanied by multiple congenital defects and a late-stage failing Fontan circulation," said Dr. David L.S. Morales, chief of pediatric cardiothoracic surgery at Cincinnati Children's Hospital Medical Center, which ranked in the top five.

SynCardia Certified Centers included in the list were:

  • #2 Children's Hospital of Philadelphia (CHOP)
  • #3 Texas Children's Hospital
  • #5 Cincinnati Children's Hospital Medical Center
  • #11 Children's Hospital of Wisconsin
  • #26 Mattel Children's Hospital UCLA
  • #32 Shands Hospital for Children at the University of Florida
  • #34 Phoenix Children's Hospital

In addition to the seven hospitals listed above, #9 Lucile Packard Children's Hospital at Stanford and #43 Arkansas Children's Hospital have completed the first two phases of SynCardia's four-phase certification program and are ready to perform their first proctored implant once an appropriate patient has been identified.

Clinical research, surgical survival and ability to prevent bloodstream infections were among the factors making up 75% of the score used for the rankings. The other 25% reflects how many of 450 pediatric cardiologists and heart surgeons surveyed in 2011, 2012 and 2013 recommended the hospital.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia
Connect with SynCardia on LinkedIn - http://www.linkedin.com/company/syncardia-systems-inc.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, ... The global anti-obesity drugs market is expected ... of the forecast period and CAGR of 38.7% in the second ... at a CAGR of 32.8% from 2016 to 2027. The market ... and $24,063 million in 2027. ...
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
Breaking Medicine Technology:
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 ... ... nutritional and wellness products to enhance people’s everyday lives, recently attended the January ... retail buyers. , ATP Science is known for its large range of supplements ...
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
(Date:1/20/2017)... ... ... Forgive You”: a fine examination of how God handles sin, including how to let ... Stephen Miller, who, for over ten long years has been waiting to release this powerful ... Tobago, he has been serving the Lord for over twenty years, and he has been ...
(Date:1/20/2017)... ... 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful ... Lighthouse” is the creation of published author, Gene Gaapf, a retired truck driver, and ... “I have been writing since high school and have many different titles,” Gaapf mentions ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... System: an On-demand E-learning system for Clinical and Regulatory education for Physicians, ... based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , ...
Breaking Medicine News(10 mins):